SD BIOSENSOR, INC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,540 KRW | -0.09% |
|
0.00% | -7.87% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 707B 518M | Sales 2025 * | 794B 582M | Capitalization | 1,290B 945M |
|---|---|---|---|---|---|
| Net income 2024 * | -48B -35.18M | Net income 2025 * | -37B -27.12M | EV / Sales 2024 * | 2.05 x |
| Net Debt 2024 * | 159B 116M | Net Debt 2025 * | 193B 141M | EV / Sales 2025 * | 1.87 x |
| P/E ratio 2024 * |
-27
x | P/E ratio 2025 * |
-34.7
x | Employees | 576 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 28.21% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -0.09% | ||
| 1 month | -4.79% | ||
| 3 months | -12.53% | ||
| 6 months | -9.53% | ||
| Current year | -7.87% |
1 week
10 470.00
10 800.00
1 month
9 630.0011 290.00
Current year
9 630.0013 210.00
1 year
9 570.0021 550.00
3 years
9 570.0081 000.00
5 years
9 570.0081 000.00
10 years
9 570.0081 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Tae-Yeong Heo
CEO | Chief Executive Officer | 55 | - |
Hyo-Geun Lee
CEO | Chief Executive Officer | 60 | - |
Chul-Kyu Oh
DFI | Director of Finance/CFO | 53 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hyo-Geun Lee
CEO | Chief Executive Officer | 60 | - |
Young-Sik Cho
CHM | Chairman | 62 | - |
Sang-Kyun Cha
BRD | Director/Board Member | 66 | 23-08-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.09% | 3 M€ | -.--% | - | |
| 0.09% | 1 M€ | +3.49% | - | |
| 0.05% | 0 M€ | +4.29% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 10,540 | -0.09% | 108,967 |
| 24-05-08 | 10,550 | -1.22% | 77,307 |
| 24-05-07 | 10,680 | +1.33% | 74,949 |
| 24-05-03 | 10,540 | +0.48% | 60,075 |
| 24-05-02 | 10,490 | -0.47% | 64,723 |
End-of-day quote Korea S.E., May 08, 2024
More quotes
SD Biosensor Inc is a Korea-based company mainly engaged in the development and sale of in vitro diagnostics. The Company is engaged in the immunochemical diagnosis, molecular diagnosis, point-of-care diagnosis (POCTs), and self blood glucose measurement business. The Company is engaged in the research, development and sale of products such as rapid immunochemical diagnosis products, immunochemical fluorescence diagnosis products, molecular diagnosis products, enzyme immunological reaction diagnosis products and others. The Company distributes its products within domestic market and to overseas markets.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
10,540
KRW
Average target price
10,000
KRW
Spread / Average Target
-5.12%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.87% | 946M | |
| -1.34% | 12.58B | |
| -1.64% | 8.51B | |
| +0.09% | 5.29B | |
| +22.42% | 5.16B | |
| -0.09% | 4.55B | |
| -52.84% | 3.04B | |
| +20.02% | 3B | |
| +31.92% | 2.17B | |
| -2.45% | 1.92B |
- Stock Market
- Equities
- A137310 Stock